FATE
FATE THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$2.53
+0.40%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.56
From 52W high−18.65%
Volume4.13M
Market cap$303.15M
P/E (TTM)—
P/S (TTM)46.7x
Div yield—
Key dataSep 18, 2026
Open
$2.56
From 52W high
−18.65%
Volume
4.13M
Market cap
$303.15M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
P/E (TTM)
—
RSI (14)
51.1
MomentumView details →
1D Return
+0.40%
YTD Return
+152.90%
SummaryUpdated Jun 1, 2026
Fate Therapeutics, Inc. (NASDAQ:FATE) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in San Diego, California. The company went public in 2013 and has established itself as a pioneer in developing off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). Fate Therapeutics focuses on creating programmed cellular treatments for cancer and autoimmune disorders, representing a cutting-edge approach to cell therapy that could potentially transform how these diseases are treated.
Similar companies
Latest newsMore news →
Fate Therapeutics reported a Q2 2026 loss of $0.25 per share, beating the Zacks Consensus Estimate of a $0.28 loss and improving from a $0.29 loss a year earlier.38d agoFate Therapeutics dosed the first lupus nephritis patient in its Phase 2 potentially registrational trial RECLAIM-LN, utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy, with the patient treated as an outpatient with same-day discharge.38d ago